STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model

Joanna M Day, Paul A Foster, Helena J Tutill, Fabien Schmidlin, Christopher M Sharland, Jonathan D Hargrave, Nigel Vicker, Barry V L Potter, Michael J Reed, Atul Purohit

    Research output: Contribution to journalArticlepeer-review

    13 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model'. Together they form a unique fingerprint.

    Medicine & Life Sciences